Randomized Study Comparing i.v. Busulfan (Busilvex) Plus Fludarabine (BuFlu) Versus Busilvex Plus Cyclophosphamide (BuCy2) as Conditioning Regimens Prior AlloHSCT in Patients (Age ≥ 40 and =<65 Years) With AML in Complete Remission

Trial Profile

Randomized Study Comparing i.v. Busulfan (Busilvex) Plus Fludarabine (BuFlu) Versus Busilvex Plus Cyclophosphamide (BuCy2) as Conditioning Regimens Prior AlloHSCT in Patients (Age ≥ 40 and =<65 Years) With AML in Complete Remission

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Busulfan (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Acute myeloid leukaemia; Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Sep 2015 Results published in the Lancet Oncology.
    • 02 Aug 2013 Planned end date changed from 1 Jun 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 02 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top